Increased intraplatelet and urinary transforming growth factor-beta in patients with multiple myeloma.
The concentrations of transforming growth factor-beta (TGF-beta) in platelets, plasma and urine from 27 patients with multiple myeloma (MM) and from 22 normal controls were measured by sandwich enzyme-linked immunosorbent assay using a monoclonal antibody specific for human TGF-beta 1+2+3. A significantly increased intraplatelet TGF-beta (24.6 +/- 9.6 vs. 17.8 +/- 8.8 ng/10(5) platelets, p < 0.01) and urinary TGF-beta (1.4 +/- 0.8 vs 1.0 +/- 0.4 ng/mg Cr, p < 0.02) were observed in MM patients compared with normal controls. The mean platelet TGF-beta level in MM patients with osteolytic lesions was more increased than in those without osteolytic lesions (29.6 +/- 7.7 vs 18.4 +/- 8.2 ng/10(5) platelets, p < 0.001). In this study, we evaluated the possible role of TGF-beta in the pathogenesis of myeloma, especially in osteolytic lesions.
Jiang
X
X
Third Department of Internal Medicine, Gumma University School of Medicine, Maebashi, Japan.
Kanai
H
H
Hiromura
K
K
Sawamura
M
M
Yano
S
S
D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal; D001792:Blood Platelets / Q000378:metabolism*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006400:Hematocrit; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000378:metabolism* / Q000473:pathology; D010014:Osteolysis / Q000473:pathology; D012680:Sensitivity and Specificity; D016212:Transforming Growth Factor beta / Q000097:blood / Q000378:metabolism* / Q000652:urine; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D016212:Transforming Growth Factor beta